-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $90

Benzinga·08/03/2026 21:19:56
语音播报
Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $82 to $90.